Cumberland Pharma Q2 revenue $10.9M (+6% YoY); net income $0.9M

CUMBERLAND PHARMACEUTICALS INC

2024-Q2 EPS reported $0.07 revenue$20,113,515

Q2 net revenue $10.9M (+6% vs prior year, +18% sequential); YTD revenue $20.1M.
Q2 net income $0.9M ($0.06/diluted share); YTD net income $1.1M ($0.07/share).
Adjusted Q2 earnings $2.3M ($0.16/share); YTD adjusted $4.0M ($0.27/share).
FDA approved Caldolor for infants (3-6 months) in May; study results published June.
Received $2.8M in FDA barrier-to-innovation fee waivers in June 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.